Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center's research programs.
Researchers find that ASTX727, a new oral combination therapy, can prolong survival in TP53-mutated MDS.
Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.
